Luis J. Montaner, DVM, DPhil

faculty photo
Wistar Institute Professor of Medicine (Infectious Diseases)
Department: Medicine
Graduate Group Affiliations

Contact information
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Office: 215-898-9143
Lab: 215-898-3934
Kansas State University, 1989.
M.Sc. (Veterinary Pathology)
Kansas State University, 1991.
D.V.M. (Veterinary Medicine)
Kansas State University, 1991.
D.Phil. (Experimental Pathology)
University of Oxford, 1995.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research Interests
Our goal is to develop a better understanding of HIV-1 immunopathogenesis and new immune-based strategies of anti-HIV therapy that are better tolerated and more sustainable for patient populations than the life-long use of antiretroviral therapy.

Research Description

The Montaner laboratory is investigating mechanisms of disease in HIV-1 infection and novel approaches to augment immune function by combining virological and immune-based research on patient-derived material as well as by using laboratory models of virus infection. The work is focused on 1) regulation of innate immunity, 2) identifying new mechanisms of immunodeficiency and discovering new approaches to reverse them, 3) exploring new therapy management practices, and 4) understanding the relationship between immune antiviral responses and control of HIV-1 infection.

Current Research Activities and Interests

Innate Immunity & HIV-1 Infection: Dendritic cells & Natural Killer Cells Direct or indirect interactions of viral particles with innate and specific adaptive immunity effector cells affects the cross talk between antigen presenting cells (APCs), NK cells and the antigen specific T and B-lymphocytes, and may contribute to regulate HIV disease progression. Specifically, we are pursuing analysis of the effects of HIV infection in macrophages, dendritic cells and Natural Killer cells.

A relationship between levels of HIV replication and innate cell function is supported by our preliminary data on DC and NK subset changes and viral replication in HIV-infected individuals showing an impairment of NK cell responses, APC endocytic uptake, differential expression of cell surface molecules associated with APC function, increased APC apoptosis, decreased IL-12 secretion, decreased IFN-? secretion and a loss of plasmacytoid dendritic cells (PDCs) and myeloid dendritic cells (MDCs) in PBMC. Based on these observations and the observed effects of antiretroviral therapy on DC and NK cell subsets, the inverse correlation between viral load and DC subsets in untreated HIV positive subjects and our observations of augmented NK lytic activity by activated DC, we are addressing longitudinal analysis and mechanistic experiments on DC/HIV interactions to test the hypothesis that HAART-mediated viral suppression restores mature NK and DC subsets necessary to activate innate mechanisms of antiviral control through lysis of infected cells. The long-term goal of this area of focus is to define the contribution of two major components of the innate immune system (accessory and Natural Killer cells) in controlling HIV replication thereby modifying disease progression. The short-term goal of our effort is to address the consequences of immune reconstitution on innate immunity following antiretroviral therapy, with particular emphasis on correlates of DC and NK cell functions and the consequences of HIV interactions with DC subsets. While adaptive HIV-specific immune responses continue to be an area of active investigation in AIDS research, the potential contribution of innate immune response, such as the relationship between DC subsets, disease progression and its consequences on other innate functions such as NK function remains largely unexplored in HAART settings. This study represents a hypothesis-driven collaborative effort by The Wistar Institute, the Infectious Disease Division of the University of Pennsylvania Hospital, Philadelphia FIGHT, Schering-Plough, Becton Dickinson, The Women's Interagency Study Cohort and the Multiple AIDS Cohort Study (MACS).

Selected Publications

Neergard, R., Jones, N., Roebuck, C., Rendle, K.A., Barbati, Z., Peterson, B., Tebas, P., Mounzer, K.C., Metzger, D.S., Montaner, L.J.: “I know that I was a part of making a difference”: Participant motivations for joining a cure-directed HIV trial with an analytical treatment interruption. AIDS Research and Human Retroviruses Aug 2023.

Dubé, K., Peterson, B., Jones, N.L., Onorato, A., Carter, W.B., Dannaway, C., Johnson, S., Hayes, R., Hill, M., Maddox, R., Riley, J.L., Shull, J., Metzger, D., Montaner, L.J: Community Engagement Group Model in Basic and Biomedical Research: Lessons Learned from the BEAT-HIV Delaney Collaboratory Towards an HIV-1 Cure. Research Involvement & Engagement 2023 Jun 2023.

Tebas, P., Lynn, K.M., Azzoni, L., Cocchella, G., Papasavvas, E., Fair, M., Reeves, J.D., Petropoulos, C., Lalley-Chareczko, L., Kostman, J.R., Short, W.R., Mounzer, K., Montaner, L.J. : Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons. AIDS Apr 2023.

Tietjen, I., Schonhofer, C., Sciorillo, A., Naidu, M.E., Haq, Z., Kannan, T., Kossenkov, A.V., Rivera-Ortiz, J., Mounzer, K., Hart, C., Gyampoh, K., Yuan. Z., Beattie, K.D., Rali, T., Shuda McGuire, K., Davis, R.A., Montaner, L.J. : The natural stilbenoid (-)-hopeaphenol inhibits HIV transcription by targeting both PKC- and NK-kappaB-signaling and cyclin-dependent kinase 9. Antimicrobial Agents and Chemotherapy Apr 2023.

Zhou, W., Liu, H., Yuan, Z., Zundell, J., Towers, M., Lin, J., Lombardi, S., Nie, H., Britten, B. Yang, T., Wang, C., Liao, L., Goldman, A., Kannan, T., Kossenkov, A., Drapkin, R., Montaner, L.J., Claiborne, D., Zhang, N. Wu, S., Zhang, R.: Targeting the mevalongate pathway suppresses ARID1A inactivated cancers by driving pyroptosis. Cancer Cell Apr 2023.

Yuan, Z., Giron, L., Hart, C., Gyampoh, A., Koshy, J., Hong, K.Y., Niki, T., Premeaux, T.A., Ndhlovu, L.C., Montaner, L.J.*, Abdel-Mohsen, M.* : Human galectin-9 promotes the expansion of HIV reservoirs in vivo in humanized mice. AIDS Mar 2023.

Zhang, C., Lum, K.Y., Taki, A.C., Gasser, R.B., Byrne, J.J., Montaner, L.J., Tietjen, I., Avery, V.M., Davis, R.A. : Using a bioactive Eremophila-derived serrulatane scaffold to generate a unique carbamate library for anti-infective evaluations. Journal of Natural Products Mar 2023.

Schnoor, M., Scott, M.J., Montaner, L.J. : Reinvigorating the JLB experience. J. Leukoc. Biol. Mar 2023.

Williams, D.E., Cassel, J., Zhu, J.L., Yang, J.X., de Voogd, N.J., Matainaho, T., Salvino, J.M., Wang, Y.A., Montaner, L.J., Tietjen, I., Andersen, R.J.: Thorectidiol Isolated from the Marine Sponge Dactylospongia elegans Disrupts Interactions of the SARS-CoV-2 Spike Receptor Binding Domain with the Host ACE2 Receptor. J Nat Prod. Mar 2023.

Islam, M.S., Wang, X., Abdel-Mohsen, M., Chen, X. Montaner, L.J. : Tissue injury and leukocyte changes in post-acute SARS-CoV-2: Review of 2833 post-acute patient outcomes per immune dysregulation and microbrial translocation in long COVID. Journal of Leukocyte Biology Mar 2023.

back to top
Last updated: 09/11/2023
The Trustees of the University of Pennsylvania